Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Inhibitor
Anticancer agent 140 is a compound designed as a parasite inhibitor, exhibiting significant potential for anticancer and antiparasitic activities. This reagent targets specific cellular pathways, making it valuable for research in cancer biology and parasitology. Its effectiveness in inhibiting parasite proliferation underscores its relevance in drug discovery and development for related diseases. -
Parasite Inhibitor
Mirincamycin hydrochloride is a potent inhibitor of malaria, specifically targeting the early liver stages of Plasmodium. This compound demonstrates protective effects, effectively preventing the progression of the parasite during its initial infection phase. However, it is important to note that Mirincamycin does not eliminate dormant liver stages, as observed in studies utilizing a rhesus monkey model. This characteristic limits its applicability in certain therapeutic scenarios against malaria. -
Parasite Inhibitor
Allylpyrocatechol is a parasite inhibitor known for its antimalarial activity. This compound has been validated for its efficacy both in vitro and in vivo, demonstrating significant potential in combating malaria. Additionally, structure-activity relationship analyses of its analogs have been conducted, providing insights into the mechanisms underlying its biological effects. Its application in research can contribute to the development of novel antimalarial therapies. -
Parasite Inhibitor
BiPNQ is a potent inhibitor of Trypanosoma cruzi, the protozoan responsible for Chagas disease. This compound effectively disrupts the biological processes of the parasite, making it a valuable tool for research focused on the treatment of Chagas disease and the development of antiparasitic therapies. Its inhibitory activity may help elucidate the mechanisms of infection and potential therapeutic targets. -
Antileishmanial Agent
Antileishmanial agent-18 is an effective inhibitor of Leishmania donovani promastigote growth, targeting the parasite responsible for visceral leishmaniasis. This compound demonstrates notable antileishmanial activity while exhibiting a low cytotoxicity profile in host cells, making it a valuable tool for research into leishmaniasis treatment options. Its application is relevant in studies aimed at understanding parasite biology and developing new therapeutic strategies against leishmaniasis. -
Parasite Inhibitor
Ludaconitine, derived from Aconitum spicatum (Bruhl) Stapf, functions as a potent inhibitor of parasites. It demonstrates significant antileishmanial activity, exhibiting an IC50 of 36.10 μg/mL. This compound is valuable for research applications focused on leishmaniasis and the exploration of novel antiparasitic agents. -
Anti-parasite Agent
PAM 1392 is an anti-parasitic agent with demonstrated efficacy against Plasmodium berghei in murine models, as well as P. cynomolgi and P. knowlesi in non-human primates. Additionally, it exhibits significant anti-Trypanosoma cruzi activity in murine tissue cultures and acts against hemolytic streptococci in vitro. The dual antimalarial and antitrypanosomal properties of PAM 1392 make it a valuable compound for research focused on drug-resistant malaria and related parasitic diseases. -
Antileishmanial Agent
Antileishmanial agent-5 is a ribonucleoside analogue that exhibits potent activity against Leishmania infantum and Trypanosoma cruzi. It demonstrates effective antileishmanial properties, with EC50 values of 0.68 μM and 0.83 μM, respectively. This compound serves as a valuable tool for research applications focused on the treatment of leishmaniasis and Chagas disease. -
Parasite Inhibitor
Ep vinyl quinidine, an epi-vinyl stereoisomer of Quinidine, serves as a targeted inhibitor of parasitic activity. This compound exhibits significant potential in malaria research, leveraging its capabilities as a selective cytochrome P450db inhibitor. Additionally, it functions as a potassium channel blocker with an IC50 of 19.9 μM, positioning it as a valuable tool for investigating anti-parasitic mechanisms and therapeutic interventions. -
Antileishmanial Agent
DNDI-VL-2098 is an orally active antileishmanial agent targeting Leishmania parasites. It demonstrates high permeability and in vitro metabolic stability while selectively inhibiting CYP2C19, with an IC50 of 0.47 μM, without affecting other major CYP enzymes at concentrations up to 12.5 μM. This compound exhibits favorable pharmacokinetic properties across various animal models, including mice, hamsters, rats, and dogs, with moderate to high plasma protein binding. DNDI-VL-2098 is a valuable reagent for the study of visceral leishmaniasis. -
Parasite Inhibitor
Antileishmanial agent-1 specifically targets Leishmania parasites, demonstrating potent inhibitory activity against L. amazonensis promastigotes with an IC50 of 15.52 μM and intracellular amastigotes with an IC50 of 4.10 μM. This compound is valuable for research focused on leishmaniasis treatment, facilitating studies on parasite bioenergetics and drug resistance mechanisms. Its ability to effectively inhibit parasite growth makes it a significant tool in the development of antileishmanial therapies. -
Antileishmanial Agent
Antileishmanial agent-15 primarily targets Leishmania spp. and exhibits significant antileishmanial activity. This compound demonstrates cytotoxic effects against L. major promastigotes and amastigotes, with IC50 values of 0.78 μM and 0.99 μM, respectively. It serves as a valuable tool for research aimed at developing treatments for leishmaniasis. -
Parasite Inhibitor
Melilotigenin C is a natural product derived from the genus Erythrina, primarily acting as a parasite inhibitor. It exhibits significant antiplasmodial activity, making it a candidate for studies focused on malaria treatment. Additionally, Melilotigenin C demonstrates antimycobacterial properties and presents potential for cytotoxicity research, contributing to the exploration of new therapeutic agents against infectious diseases. -
Parasite Ubiquinol Oxidation Site Inhibitor
ELQ-121 is a potent inhibitor targeting the ubiquinol oxidation site in parasites. It exhibits remarkable antimalarial activity, with an IC50 of 0.05 nM against both chloroquine-sensitive and multidrug-resistant strains of P. falciparum in vitro. Additionally, ELQ-121 demonstrates high efficacy against T. gondii and N. caninum, with IC50 values below 1 nM, and suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM, accompanied by mitochondrial disruption. Furthermore, the compound can be formulated as a polyethylene glycol carbonate ester prodrug, showing in vivo efficacy against P. yoelii in mice, making it a valuable tool for antimalarial research. -
Parasite Inhibitor
BRD5018 is a selective antimalarial agent that targets Plasmodium parasites. This compound functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its ability to facilitate this reaction expands its utility in chemical biology applications, particularly in the development of novel therapeutic strategies against malaria. -
Parasite
trans-Methylisoeugenol acts as an insect chemosterilant, primarily targeting parasites. Isolated from Acorus calamus L., this compound demonstrates significant biological activity by inhibiting reproductive capabilities in various insect species. It has applications in pest control research and studies focused on parasitic insect management. -
Antileishmanial Agent
Antileishmanial agent-11 is a potent antileishmanial compound that primarily targets Leishmania species. It exhibits significant antiprotozoal activity, with IC50 values of 28.3 μM against Leishmania braziliensis, 24.8 μM against Leishmania infantum, and 13.0 μM against Trypanosoma cruzi. This compound is valuable for research focused on leishmaniasis and Chagas disease, providing a useful tool for understanding protozoan infections and exploring potential therapeutic strategies. -
Antileishmanial Agent
Antileishmanial agent-9 is a potent and selective compound targeting Leishmania donovani, exhibiting an IC50 value of 4.01 μM. This agent demonstrates significant antileishmanial activity while maintaining relatively low cytotoxicity in L-6 cells, with an IC50 of 40.1 μM. It serves as a valuable tool for research applications focusing on leishmaniasis treatment and drug development. -
Parasite
Clioxanide is an investigational agent targeting the parasite Fasciola hepatica, known for causing liver fluke infections. Research indicates that Clioxanide demonstrates limited efficacy against both 4-week-old and 19-week-old liver flukes at doses of 135 mg/kg and 200 mg/kg. Importantly, no significant toxicological effects were noted in laboratory mice, suggesting a favorable safety profile. This compound may serve as a valuable addition to studies aimed at developing treatments for liver fluke infections in livestock species, although its effectiveness warrants further investigation. -
Parasite Modulator
TCMDC-136230 is a novel modulator of calcium dynamics in malaria parasites. It effectively disrupts calcium regulation while showing minimal inhibition of heme crystallization. This compound is valuable for research focused on developing new antiparasitic therapies and understanding the molecular mechanisms underlying malaria pathogenesis. -
Parasite Inhibitor
Antimalarial agent 2 is a novel compound that targets Plasmodium parasites, displaying a rapid in vitro killing profile. This reagent demonstrates potent antiparasitic activity, making it a valuable tool for research into malaria treatment and the development of effective antimalarial therapies. Its oral efficacy indicates potential for further exploration in therapeutic applications against malaria. -
Parasite Modulator
TCMDC-125457 is a potent parasite modulator that induces calcium redistribution while minimally inhibiting heme crystallization. This compound has shown high efficacy in a single-dose combination with artesunate, particularly against tightly synchronized artemisinin-resistant ring-stage parasites. Its unique mechanism and activity position TCMDC-125457 as a valuable tool for research into antimalarial therapies and the understanding of drug resistance in parasitic infections. -
Anti-parasite Agent
Lychnopholide is a sesquiterpene lactone targeting Trypanosoma cruzi, demonstrating significant anti-trypanosomal activity. This compound has been shown to effectively reduce toxicity to mammalian cells when encapsulated in nanocapsules, enhancing its therapeutic potential. Lychnopholide is utilized in research focused on Chagas disease, providing valuable insights in mouse model studies for potential treatment strategies. -
Antileishmanial Agent
Antileishmanial agent-14 is a sulfuretin analog targeting Leishmania donovani, demonstrating significant antileishmanial activity. With an IC50 of 4.1 μM against promastigotes and an IC50 of 11.1 μM against amastigotes, this compound shows promise for inhibiting the infection cycle of the parasite. Its effectiveness makes it a valuable tool for research into leishmaniasis treatment and further investigation of related therapeutic strategies. -
Parasite Inhibitor
Carbarsone, or p-ureidobenzenearsonic acid, primarily functions as a parasite inhibitor with notable efficacy as an amebicide. Historically utilized in human and veterinary medicine, it has been incorporated into poultry and swine feed to mitigate conditions such as blackhead in turkeys, often in conjunction with antibiotics. Its relatively low acute toxicity has prompted research into its safety as a food additive, with studies indicating minimal carcinogenic risk under chronic ingestion, similar to other arsanilic acid derivatives. Carbarsone is metabolized to arsanilic acid, which has been investigated in high-dose studies in canine models. -
Antileishmanial Agent
Antileishmanial Agent-17 is a coumarin hybrid compound that targets the folate pathway enzymes pteridine reductase and dihydrofolate reductase-thymidylate synthase (DHFR-TS). It exhibits significant antileishmanial activity, demonstrating an IC50 of less than 0.78 μM, with a maximum potency of 0.40 μM against promastigotes and 0.68 μM against amastigotes. Moreover, it is non-toxic to normal VERO cells, making it a promising candidate for research in leishmaniasis treatment. -
Parasite Inhibitor
MMV666810 is a potent parasite inhibitor that targets asexual stages of parasites, exhibiting an IC50 of 5.94 nM. Notably, it demonstrates a 3.3-fold selectivity for late-stage gametocytes over earlier stages, with IC50 values of 179 ± 8 nM for late-stage and 603 ± 88 nM for early-stage gametocytes. This compound is valuable for research applications focused on antimalarial drug development and understanding gametocyte biology. -
Antileishmanial Agent
Antileishmanial agent-13 is a quinoline-isatin hybrid that functions as an effective antileishmanial agent targeting the L. major strain of Leishmania. This compound exerts its activity through an anti-folate mechanism, demonstrating potent inhibition against both promastigote and amastigote forms, with IC50 values of 0.604 μM and 0.508 μM, respectively. Its significant biological activity makes it a valuable reagent for research in Leishmaniasis treatment and drug development. -
Antileishmanial Agent
Sitamaquine tosylate is an 8-aminoquinoline analog that functions as an antileishmanial agent by inhibiting mitochondrial complex II (succinate dehydrogenase). This compound exhibits significant biological activity through its ability to rapidly accumulate in the acidic compartments of Leishmania species, particularly in acidocalcisomes, due to its lipophilic weak base characteristics. Sitamaquine tosylate is utilized in research aimed at understanding and combating leishmaniasis. -
Parasite Inhibitor
3-ANOT is a metabolite of Dinitolmide, functioning primarily as a parasite inhibitor. It demonstrates significant efficacy against coccidia, making it essential for research into antiparasitic mechanisms. 3-ANOT is applicable in studies focused on the prevention and treatment of parasitic infections in livestock, especially in poultry. -
Parasite Inhibitor
IWY357 is a potent inhibitor of Plasmodium falciparum, specifically targeting the blood stage of the parasite. This compound exhibits significant efficacy in disrupting the life cycle of the parasite, making it a valuable tool for researchers investigating malaria infection mechanisms and developing therapeutic strategies. Its long-acting properties can contribute to the understanding of parasite biology and assist in the design of novel anti-malarial drugs. -
Antileishmanial Agent
Antileishmanial agent-12 is a potent anti-leishmanial agent targeting protozoan parasites. It exhibits significant antiprotozoal activity against Leishmania braziliensis and Leishmania infantum, showing IC50 values of 14.9 μM and 21.3 μM respectively, as well as against T. cruzi with an IC50 value of 9.3 μM. This compound is applicable in research focused on the treatment of leishmaniasis and Chagas disease, contributing to the development of new therapeutic strategies against these infections. -
Parasite Inhibitor
Nopol is a quinoline derivative that acts as a potent inhibitor of the asexual blood stage of Plasmodium falciparum. Its structural variations result in differing biological activities against various Plasmodium strains, with certain derivatives exhibiting submicromolar EC50 values for specific strains. This compound is valuable for research focused on malaria treatment and the development of antimalarial agents. -
Antileishmanial Agent
Antileishmanial agent-8 is a targeted antileishmanial agent that exhibits potent activity against Leishmania donovani with an IC50 value of 5.64 μM. This compound demonstrates a favorable safety profile, exhibiting relatively low cytotoxicity in L-6 cells with an IC50 of 73.9 μM. Antileishmanial agent-8 is ideal for research applications focused on developing treatments for leishmaniasis. -
Parasite Inhibitor
Phebestin is a compound that exhibits potent antimalarial activity by inhibiting the growth of Plasmodium spp. It demonstrates significant efficacy in both in vitro and in vivo studies. Additionally, Phebestin interacts with key enzymes associated with the Plasmodium life cycle, making it a valuable tool for research in parasitology and the development of novel antimalarial therapies. -
Parasite Inhibitor
M&B 5124 is a potent inhibitor targeting Schistosoma mansoni, a pathogenic trematode responsible for schistosomiasis. This compound demonstrates significant antiparasitic activity in murine models, making it a valuable tool for research into therapeutic strategies against schistosomiasis. Its efficacy positions it as a candidate for further studies aimed at understanding parasitic infections and developing new treatment options. -
Antileishmanial Agent
Antileishmanial agent-31 is a pyrazole derivative that targets Leishmania species. It exhibits significant anti-leishmanial activity, with an IC50 value of 35.53 μg/mL, indicating its potential effectiveness in combating leishmaniasis. This compound demonstrates high stability, making it suitable for research applications aimed at understanding and developing treatments for Leishmania infections. -
Parasite
Atropine Oxide is a derivative of Atropine that functions as a competitive antagonist at muscarinic acetylcholine receptors M1, M2, M3, M4, and M5. This compound exhibits significant biological activity in blocking parasympathetic neuro-transmission. It is primarily utilized in research applications focused on the treatment of specific nerve agent and pesticide poisonings. -
Parasite
Cardol triene is a phenolic compound that serves as a competitive and irreversible inhibitor of mushroom tyrosinase, with an IC50 of 22.5 μM. This compound exhibits significant schistosomicidal activity, demonstrating the ability to eliminate 25%, 75%, and 100% of Schistosoma mansoni worms within 24 hours at concentrations of 50, 100, and 200 μM, respectively. Additionally, Cardol triene is utilized as a precursor in the synthesis of bis-benzoxazines, making it a valuable reagent for research in parasitology and synthetic chemistry. -
Parasite Inhibitor
Melarsonyl dipotassium is a potent anthelmintic agent that targets various parasitic organisms. By interfering with metabolic processes in parasites, it exhibits significant inhibitory activity, making it valuable for research in parasitology and drug development. This compound is particularly relevant in studying the mechanisms of anthelmintic resistance and developing novel therapeutic strategies against parasitic infections. -
Parasite Inhibitor
trans-Cinnamic anhydride is a parasite inhibitor with a primary target of Plasmodium falciparum. This compound, isolated from Cinnamomum zeylanicum, demonstrates moderate antimalarial activity. It is utilized in pharmacological studies aimed at developing therapeutic agents against parasitic infections. -
Parasite
Pyriftalid is a novel insecticide that exhibits potent inhibitory activity against a range of pests. Its primary application in agriculture focuses on effectively managing pest populations in crops, which in turn enhances crop yield and quality. Additionally, Pyriftalid is being investigated for its potential to bolster plant resistance against both pests and diseases, making it an important tool in sustainable agricultural practices. -
Parasite Inhibitor
Epsiprantel is a potent anti-Echinococcus compound that functions as a parasite inhibitor, effectively inducing the death of protoscolex, larvae, and adult stages of the parasite in vitro. In vivo studies demonstrate its higher efficacy against mature worms compared to larvae, making it a valuable tool for research into Echinococcus infections and potential therapeutic strategies. Epsiprantel is characterized by its safety profile, showing no adverse side effects in tested models. -
Parasite Inhibitor
6-O-Methacrylate is a trilobolide derivative derived from the leaves of Wedelia trilobata, functioning primarily as a parasite inhibitor. It exhibits significant antimalarial activity with an IC50 of 8.9 μg/mL against the Plasmodium falciparum parasite. Additionally, 6-O-Methacrylate demonstrates antiviral properties by inhibiting the tobacco mosaic virus (TMV). This compound is valuable for research in parasitology and virology. -
Antileishmanial Agent
Eugenitin is a polyketide compound derived from the fungus Mycoleptodiscus indicus, serving as an antileishmanial agent. It demonstrates significant inhibitory activity against Leishmania major, with an LD50 of 39.9 μM, while exhibiting low cytotoxicity against various human cancer cell lines (IC50 > 131 μM). This profile makes Eugenitin a valuable compound for research focused on leishmaniasis and cancer biology. -
Parasite Inhibitor
Cyclobendazole is a benzimidazole derivative targeting protozoan parasites. It demonstrates potent in vitro activity against Trichomonas vaginalis and Giardia lamblia, with IC50 values of 1.1 μg/mL and 0.047 μg/mL, respectively. This compound is useful in research applications focused on combating protozoal infections and studying their biological pathways. -
Antileishmanial Agent
Antileishmanial agent-7 is an effective antileishmanial compound targeting Leishmania donovani. It demonstrates potent biological activity, with IC50 values of 6.89 μM against L. donovani and 259 μM against L-6. This agent can be utilized in research focused on leishmaniasis treatment and drug development. -
Parasite Inhibitor
Fenbendazole sulfone is a benzimidazole anthelmintic agent that acts as a parasite inhibitor. It is a minor metabolite of fenbendazole, demonstrating significant activity against various helminths. This compound is primarily utilized in research focused on parasitic infections and anthelmintic drug development. -
Parasite Inhibitor
Anti-infective agent 9 is an inhibitor of Plasmodium falciparum, exhibiting an IC50 of 600 nM, which targets metabolic pathways by downregulating pyruvate levels and interfering with the TCA cycle. This compound demonstrates favorable metabolic stability and low toxicity in human liver cells, making it a viable candidate for further research into antimalarial therapies. Additionally, studies suggest that its mechanism of action may involve pathways beyond 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), highlighting its potential as a multifaceted therapeutic agent in combating malaria. -
Parasite Inhibitor
Lettowienolide is a geranylbenzoquinonoid that targets the Plasmodium falciparum malaria parasite. It demonstrates mild in vitro inhibitory activity, with an IC50 of approximately 20 μg/mL. This compound is relevant for research applications focusing on malaria treatment and the exploration of new therapeutic agents against parasitic infections.
